Recently, tumor immunotherapy based on T cells has given patients new hope, however, its problem of low response rate sometimes leads to poor prognosis. That means new strategies sensitizing cancer immunotherapy are urgently needed. Here, Rongchen Shi et al give an overview of the characteristics of tumor microenvironment, the metabolic changes of tumor‐associated immune cells, and the regulatory role of metabolic reprogramming in cancer immunotherapy.

Fig. 1 Components of the TME. The TME consists of cellular and extracellular components.

 

 

 

Article Access: https://onlinelibrary.wiley.com/doi/10.1002/mco2.6

 

 

                                                                           

Website for MedComm: https://onlinelibrary.wiley.com/journal/26882663

Looking forward to your contributions.